About David Cheishvili
An epigenetics and molecular biology professional with experience in the academic, public, and private sectors. Holds a PhD in biochemistry and currently serves as Chief Innovation Officer at epiMedTech Global (Singapore) and as an affiliate member at McGill University (Canada)
Recent Comments
Great work, is this very specific to HCC? Have you tested other caner types`?
Thank you for your kind words and for your interest in our work. This high-throughput test has been specifically developed for the early detection of Hepatocellular Carcinoma (HCC). To ensure its specificity to HCC, the assay underwent testing on individuals with 15 different non-HCC cancers (Fig. 5, 6 and 7 of the manuscript).